Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
暂无分享,去创建一个
D. Tregouet | M. Humbert | V. Drouin‐Garraud | X. Jaïs | B. Girerd | G. Simonneau | O. Sitbon | D. Montani | F. Coulet | D. O’Callaghan | F. Soubrier | B. Sztrymf | A. Fraisse | A. Reis | A. Yaici
[1] M. Humbert,et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. , 2010, European heart journal.
[2] ณัฐพงศ์ เจียมจริยธรรม. Update in Pulmonary Hypertension , 2010 .
[3] M. Humbert,et al. Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre , 2009, European Respiratory Review.
[4] G. Filippatos,et al. Guidelines for the diagnosis and treatment of pulmonary hypertension , 2009 .
[5] W. Chung,et al. [Genetics and genomics of pulmonary arterial hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[6] J. Granton,et al. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia , 2009, European Respiratory Journal.
[7] M. Humbert. Update in pulmonary hypertension 2008. , 2009, American journal of respiratory and critical care medicine.
[8] V. Lip,et al. Clinical features of pulmonary arterial hypertension in young people with an ALK1 mutation and hereditary haemorrhagic telangiectasia , 2009, Archives of Disease in Childhood.
[9] C. Shovlin,et al. Practical Genetics , 2022 .
[10] M. Humbert,et al. Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH , 2009, European Respiratory Review.
[11] M. Humbert,et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. , 2008, American journal of respiratory and critical care medicine.
[12] J. Knowles,et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[13] M. Furutani,et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[14] E. Kulinskaya,et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia , 2007, Thorax.
[15] P. Dijke,et al. Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.
[16] R. Trembath,et al. Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension. , 2007, American journal of respiratory and critical care medicine.
[17] L. David,et al. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. , 2007, Blood.
[18] K. Lewis. Pulmonary Arterial Hypertension in France: Results from a National Registry , 2007 .
[19] P. ten Dijke,et al. Extracellular control of TGFbeta signalling in vascular development and disease. , 2007, Nature reviews. Molecular cell biology.
[20] M. Humbert,et al. Genes and Pulmonary Arterial Hypertension , 2006, Respiration.
[21] C. Ricachinevsky,et al. Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.
[22] J. Cogan,et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.
[23] Eric W. Glissmeyer,et al. Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension , 2006, Circulation.
[24] J. Loscalzo,et al. Pulmonary arterial hypertension. , 2004, Annals of medicine.
[25] C. Shovlin,et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5 , 2005, Journal of Medical Genetics.
[26] M. Humbert,et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.
[27] R. Trembath,et al. Investigation of Second Genetic Hits at the BMPR2 Locus as a Modulator of Disease Progression in Familial Pulmonary Arterial Hypertension , 2005, Circulation.
[28] R. Trembath,et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. , 2005, Circulation.
[29] D. Mccrory,et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[30] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[31] M. Humbert,et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension , 2004, Thorax.
[32] V. Cottin,et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. , 2004, American journal of respiratory and critical care medicine.
[33] S. Pinson,et al. Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France , 2004, Human mutation.
[34] A. Rustgi,et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4) , 2004, The Lancet.
[35] D. Marchuk,et al. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia , 2004, European Respiratory Journal.
[36] W. Seeger,et al. Clinical classification of pulmonary hypertension. , 2001, Clinics in chest medicine.
[37] R. Trembath,et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia , 2003, Journal of medical genetics.
[38] C. Shovlin,et al. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century , 2003, Postgraduate medical journal.
[39] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[40] ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.
[41] J. Doré,et al. Transforming growth factor beta receptor signaling and endocytosis are linked through a COOH terminal activation motif in the type I receptor. , 2001, Molecular biology of the cell.
[42] M. Humbert,et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.
[43] P. Corris,et al. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein tùype II receptor. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[44] C. Shovlin,et al. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms , 1999, Thorax.
[45] L. Rubin,et al. Primary pulmonary hypertension. , 1997, The New England journal of medicine.
[46] A. Guttmacher,et al. Hereditary hemorrhagic telangiectasia. , 1995, The New England journal of medicine.
[47] H. Plauchu,et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. , 1989, American journal of medical genetics.